Cytotoxicity of some DMC derivatives against human intrahepatic cholangiocarcinoma (KKU-M213), human squamous cell carcinoma (FaDu), human colorectal adenocarcinoma (HT-29), human mammary gland adenocarcinoma (MDA-MB-231), human lung carcinoma (A-549), human neuroblastoma (SH-SY5Y), and human normal liver hepatic cell (CL).
| Compound | Cytotoxicity (IC50, μM) | ||||||
|---|---|---|---|---|---|---|---|
| KKU-M213 | FaDu | HT-29 | MDA-MB-231 | A-549 | SH-SY5Y | CL | |
| 2a | 30.05 | 31.16 | 35.77 | 38.24 | >50 | 27.55 | 32.82 |
| 2b | 21.26 | 18.92 | 26.63 | 18.13 | 24.84 | 5.20 | 23.53 |
| 2c | 24.43 | 20.63 | 26.62 | 25.86 | >50 | 18.04 | 25.16 |
| 2d | >50 | 34.71 | >50 | 36.70 | >50 | 24.79 | 41.87 |
| 2f | 42.98 | 36.49 | 38.63 | 40.28 | >50 | 28.56 | 31.02 |
| 2g | 23.88 | 24.84 | 19.69 | 26.22 | 25.35 | 7.52 | 25.42 |
| 2h | 23.19 | 13.98 | 27.47 | 26.85 | 9.99 | 16.45 | 22.58 |
| 2i | 31.26 | 28.96 | 34.63 | 39.10 | 36.67 | 28.25 | 31.68 |
| 2k | >50 | 37.89 | 32.53 | >50 | 41.30 | 20.25 | >50 |
| 2l | 28.86 | 22.09 | 26.75 | 25.09 | 22.43 | 15.56 | 25.36 |
| 2m | 23.76 | 27.00 | 26.66 | 26.11 | 26.29 | 20.43 | 29.01 |
| 2n | 27.84 | 21.10 | 24.73 | 39.75 | >50 | 16.37 | 30.38 |
| 3c | >50 | >50 | >50 | >50 | >50 | 20.86 | 35.90 |
| 4a | 29.58 | >50 | 30.87 | >50 | >50 | >50 | >50 |
| 5f | 28.01 | 33.65 | 36.51 | 29.78 | 15.40 | 18.75 | 27.35 |
| 5g | 23.47 | 19.30 | 21.94 | 29.78 | 22.67 | 12.56 | 18.69 |
| 5k | 31.55 | 24.54 | 33.76 | >50 | 30.93 | 25.31 | 25.31 |
| 6m | >50 | >50 | 45.49 | >50 | 37.86 | 44.69 | >50 |
| DMC (1) | 29.4 | 37.57 | 38.58 | 37.64 | 19.9 | 13.1 | 15.6 |
| Ellipticine (+)a | 2.40 | 2.03 | 2.15 | 2.80 | 1.14 | 2.64 | 2.07 |
a
Ellipticine was used as a positive control for the cytotoxicity assay.